Return On Equity
-39%
Trailing 12 months · Through 31 Mar 2023
DA32 Life Science Tech Acquisition Corp. financial metrics
Period Q1 2023 · Filed not available
Key metrics snapshot
Return On Assets
0.85%
Trailing 12 months · Through 31 Mar 2023
Current Ratio
0.36x
Period-end balance · Through 31 Mar 2023
YoY relative change: -95%
Debt-to-equity
-1.4x
Period-end balance · Through 31 Mar 2023
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
-39%
Trailing 12 months · 31 Mar 2023
|
|
| Return On Assets |
0.85%
Trailing 12 months · 31 Mar 2023
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.36x
Period-end balance · 31 Mar 2023
|
-95% |
| Debt-to-equity |
-1.4x
Period-end balance · 31 Mar 2023
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Net Income (Loss) Attributable to Parent |
$1,728,190
Trailing 12 months · 31 Mar 2023
|
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$0
Period-end balance · 31 Mar 2023
|
-100% |
| Accrued Liabilities, Current |
$432,000
Period-end balance · 31 Mar 2023
|
+91% |
| Additional Paid in Capital |
$0
Period-end balance · 31 Mar 2023
|
|
| Assets |
$204,984,219
Period-end balance · 31 Mar 2023
|
+1.4% |
| Assets, Current |
$491,106
Period-end balance · 31 Mar 2023
|
-77% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$303,772
Period-end balance · 31 Mar 2023
|
-81% |
| General and Administrative Expense |
$1,428,563
Trailing 12 months · 31 Mar 2023
|
+34% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
$1,154,558
Reported period · 31 Mar 2023
|
|
| Income Tax Expense (Benefit) |
$328,947
Reported period · 31 Mar 2023
|
|
| Liabilities |
$6,952,980
Period-end balance · 31 Mar 2023
|
+18% |
| Liabilities and Equity |
$204,984,219
Period-end balance · 31 Mar 2023
|
+1.4% |
| Liabilities, Current |
$1,352,980
Period-end balance · 31 Mar 2023
|
+341% |
| Net Cash Provided by (Used in) Operating Activities |
-$395,484
Reported period · 31 Mar 2023
|
-52% |
| Nonoperating Income (Expense) |
$1,566,417
Reported period · 31 Mar 2023
|
+5120% |
| Operating Income (Loss) |
-$1,838,613
Trailing 12 months · 31 Mar 2023
|
-24% |
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 31 Mar 2023
|
0% |
| Preferred Stock, Shares Authorized |
1,000,000
Period-end balance · 31 Mar 2023
|
0% |
| Preferred Stock, Shares Issued |
0
Period-end balance · 31 Mar 2023
|
|
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 31 Mar 2023
|
|
| Retained Earnings (Accumulated Deficit) |
-$5,109,260
Period-end balance · 31 Mar 2023
|
-38% |
| Stockholders' Equity Attributable to Parent |
-$5,108,695
Period-end balance · 31 Mar 2023
|
-38% |
Comparisons, sources and research notes
Sources and sharing
DA32 Life Science Tech Acquisition Corp. Financial Facts
- Context
- Latest metrics period: Q1 2023
- Latest reported value
- Return On Equity -39%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q1 2023
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q1 2023.
- Most recent SEC facts end date on this page: 31 Mar 2023.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Benchmark Context
How Return On Equity compares
Return On Equity does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with DA32 Life Science Tech Acquisition Corp.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q1 2023.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Filing notes and source
Key facts
- DA32 Life Science Tech Acquisition Corp. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q1 2023.
- Headline metric: Return On Equity -39%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 31 Mar 2023.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2023-03-31) highlights Return On Equity -39.3%, Return On Assets 0.8%, and Current Ratio 0.36x.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -1,231,631.0 USD · through 2023-03-31 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: unavailable on a verified comparable basis
- Cash and equivalents: 303,772.0 USD · through 2023-03-31 SEC source
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Debt unavailable: no complete usd debt balance at the latest balance date
- Shares outstanding may be class-specific for multi-class issuers; prefer weighted average share tags when available
- Ticker missing for issuer
- Valuation unavailable: free cash flow is missing
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
9.3/100
Weak Confidence low
Return On Equity
-39%
Metric score 0.0/100
Return On Assets
0.85%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.36x
- Debt to Equity
- -1.4x
Strengths
No strong signals yet.
Watchpoints
Return On Equity, Return On Assets, and Current Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first